New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease

Digestive Diseases and Sciences

Volumn 41, Issue 8, 1996, Pages 1678-1681

  Friedlander, Lois ^b   Van Thiel, David H ^b   Faruki, Hawazin ^b   Molloy, Peter J ^b   Kania, Robert J ^a   Hassanein, Tarak ^b  

^a Keystone Digest Disease Consultants   (United States)

^b NONE

Author keywords

Chronic viral hepatitis C; Interferon; Treatment endpoint

Indexed keywords

INTERFERON;

ADULT; ALOPECIA; ARTICLE; CHILL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; FEVER; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029793505     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02087924     Document Type: Article

References (19)

1. Schaffner F: Introduction to viral hepatitis. In Bockus Gastroenterology, Vol. 3, 5th ed., WD Haubrich, F Schaffner, JE Berk (eds). Philadelphia, WB Saunders, 1995, pp 2035-2043
2. Hoofnagle JH: Hepatitis B. In Bockus Gastroenterology, Vol. 3, 5th ed., WD Haubrich, F Schaffner, JE Berk (eds). Philadelphia, WB Saunders, 1995, pp 2062-2081
3. Davis GL, Lau JYN. Hepatitis C. In Bockus Gastroenterology, Vol. 3, 5th ed., WD Haubrich, F Schaffner, JE Berk (eds). Philadelphia, WB Saunders, 1995, pp 2082-2114
4. Korenman J, Baker B, Waggoner J, et al: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114:629-633, 1991
5. Tassapoulos NC, Hadziyannis SJ, Wright GE: Recombinant human interferon alfa-2b in the management of acute type B hepatitis. Hepatology 10:576, 1989 (abstract)
6. Hoofnagle JH, Peters MG, Mullen KD, et al. Randomized controlled trial of a four-month course of recombinant human alpha interferon in chronic type B hepatitis. Gastroenterology 95:1318-1325, 1988
7. Perrillo RP, Schiff E, Davis GL, et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 323:295-301, 1990
8. Wong DKH, Cheung AM, O'Rouke K, et al: Effect of alpha-interferon treatment in patients with Hepatitis Be antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med 119:312-323, 1993
9. Davis GL, Hoofnagle JH: Interferon in viral hepatitis: Role in pathogenesis and treatment. Hepatology 6:1038-1041, 1986
10. Hoofnagle JH, Mullen KD, Jones DB, et al: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N Engl J Med 315:1575-1578, 1986
11. DiBisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
12. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic-hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
13. Mateo R, Faruki H, Ehrlich G, et al: Detection of hepatitis C viruses RNA in liver and plasma by RT-PCR liquid hybridization. In PCR Based Clinical Diagnostics, S Greenberg (ed). Boston, Blackwell Scientific, 1993, pp 375-397
14. Knodell RG, Ishak KG, Black WC, When TS, Craig R, Kaplowitz N, Kierman TW, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology 1:432-435, 1981
15. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon therapy is influenced by the iron content of the liver. J Hepatol 20:410-415, 1994
16. Caraceni P, Fagiuoli S, Van Thiel DH: Iron reduction therapy: Simply camouflage or a real weapon? Am J Gastroenterol 89:970-973, 1994
17. Van Thiel DH, Fagiuoli S, Caraceni P, Nadir A, Wright HI: Therapy of viral hepatitis: An iconoclast's view. Proceeding of Second International Symposium on Viral Hepatitis and Hepatocellular Carcinoma, Singapore, 1994
18. Gurakar A, Fagiuoli S, Faruki H, DeMaria N, Balkan M, Van Thiel DH, Friedlander L: Utility of HCV-RNA deterioration in hepatic tissue as an end point for Interferon treatment of chronic hepatitis C. Hepatology 1109-1112, 1995
19. Van Thiel DH, Friedlander L, Fagiuoli S, Molloy PJ, Kania RJ, Wright HI: The Oklahoma Pittsburgh experience with interferon-α in the treatment of HCV disease. J Okla State Med Assoc 88:154-161, 1995